Genprex (NASDAQ: GNPX), a clinical-stage gene therapy
company developing potentially life-changing technologies for patients with
cancer and other serious diseases, on Wednesday announced that it has entered
into securities purchase agreements with institutional investors for the
purchase and sale of 5,000,000 shares of common stock, par value $0.001 per
share, at an offering price of $3.50 each, pursuant to a registered direct
offering, priced at-the-market under Nasdaq rules. There are no warrants in the
offering. The company intends to use the proceeds from the offering, which are
anticipated to be roughly $17,500,000 before deducting fees and other estimated
offering expenses, towards the advancement of its lead clinical programs in
non-small cell lung cancer (“NSCLC”) and for working capital and general
corporate purposes. A.G.P./Alliance Global Partners is acting as lead placement
agent, and Joseph Gunnar & Co., LLC is acting as co-placement agent for the
offering. Subject to the satisfaction of customary closing conditions, the
registered direct offering is expected to close on or about February 21, 2020.
To view the full press release, visit http://ibn.fm/kLPkD
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with cancer and
other serious diseases. Genprex’s technologies are designed to administer
disease-fighting genes to provide new treatment options for large patient
populations with cancer and other serious diseases who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to in-license and develop drug candidates to further its pipeline
of gene therapies in order to provide novel treatment approaches for patients
with cancer and other serious diseases. The company’s lead product candidate, Oncoprex(TM)
immunogene therapy for non-small cell lung cancer (“NSCLC”), uses the company’s
unique, proprietary platform which delivers cancer-fighting genes by
encapsulating them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where they express
proteins that are missing or found in low quantities. In January 2020, the FDA
granted Fast Track Designation for Oncoprex in combination with AstraZeneca’s
Tagrisso(R) for the treatment of NSCLC. For more information, please visit the
company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment